These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16265126)

  • 41. The effect of sibutramine intake on resting and exercise physiological responses.
    Rotstein A; Inbar O; Vaisman N
    Ann Nutr Metab; 2008; 52(1):17-23. PubMed ID: 18230966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Central and peripheral alytesin cause short-term anorexigenic effects in neonatal chicks.
    Cline MA; Fouse DN; Prall BC
    Neuropeptides; 2008 Jun; 42(3):283-91. PubMed ID: 18384875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
    Mashiko S; Ishihara A; Iwaasa H; Moriya R; Kitazawa H; Mitobe Y; Ito J; Gomori A; Matsushita H; Takahashi T; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A
    Obesity (Silver Spring); 2008 Jul; 16(7):1510-5. PubMed ID: 18421274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Central and peripheral neuroendocrine peptides and signalling in appetite regulation: considerations for obesity pharmacotherapy.
    Atkinson TJ
    Obes Rev; 2008 Mar; 9(2):108-20. PubMed ID: 18257752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Appetite signaling: from gut peptides and enteric nerves to brain.
    Näslund E; Hellström PM
    Physiol Behav; 2007 Sep; 92(1-2):256-62. PubMed ID: 17582445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Obesity and the hepatic control of feeding behavior.
    Friedman MI
    Drug News Perspect; 2007 Nov; 20(9):573-8. PubMed ID: 18176662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weight loss medications--where do they fit in?
    Dixon JB
    Aust Fam Physician; 2006 Aug; 35(8):576-9. PubMed ID: 16894428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute and long-term effects of alkaloid extract of Mitragyna speciosa on food and water intake and body weight in rats.
    Kumarnsit E; Keawpradub N; Nuankaew W
    Fitoterapia; 2006 Jul; 77(5):339-45. PubMed ID: 16781828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple effects of sibutramine on ejaculation and on vas deferens and seminal vesicle contractility.
    Nojimoto FD; Piffer RC; Kiguti LR; Lameu C; de Camargo AC; Pereira OC; Pupo AS
    Toxicol Appl Pharmacol; 2009 Sep; 239(3):233-40. PubMed ID: 19482040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of long-term vagal stimulation on food intake and body weight during diet induced obesity in rats.
    Bugajski AJ; Gil K; Ziomber A; Zurowski D; Zaraska W; Thor PJ
    J Physiol Pharmacol; 2007 Mar; 58 Suppl 1():5-12. PubMed ID: 17443024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medications for weight reduction.
    Bray GA
    Endocrinol Metab Clin North Am; 2008 Dec; 37(4):923-42. PubMed ID: 19026940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents.
    Ortiz AA; Milardo LF; DeCarr LB; Buckholz TM; Mays MR; Claus TH; Livingston JN; Mahle CD; Lumb KJ
    J Pharmacol Exp Ther; 2007 Nov; 323(2):692-700. PubMed ID: 17671099
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological approaches to appetite suppression.
    Blundell J
    Trends Pharmacol Sci; 1991 Apr; 12(4):147-57. PubMed ID: 2063481
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peripheral mechanisms of sibutramine involving proximal gastric motility in dogs.
    Xu J; Chen JD
    Obesity (Silver Spring); 2006 Aug; 14(8):1363-70. PubMed ID: 16988078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short-term anorexigenic effects of central neuropeptide VF are associated with hypothalamic changes in chicks.
    Cline MA; Bowden CN; Calchary WA; Layne JE
    J Neuroendocrinol; 2008 Aug; 20(8):971-7. PubMed ID: 18540998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes.
    Richardson DK; Jones RB; Bailey CJ
    Horm Metab Res; 2006 Nov; 38(11):727-31. PubMed ID: 17111299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A critical review of the cannabinoid receptor as a drug target for obesity management.
    Akbas F; Gasteyger C; Sjödin A; Astrup A; Larsen TM
    Obes Rev; 2009 Jan; 10(1):58-67. PubMed ID: 18721231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression.
    Hsieh YS; Yang SF; Chiou HL; Kuo DY
    Behav Neurosci; 2007 Oct; 121(5):933-40. PubMed ID: 17907825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. C75 inhibits food intake by increasing CNS glucose metabolism.
    Wortman MD; Clegg DJ; D'Alessio D; Woods SC; Seeley RJ
    Nat Med; 2003 May; 9(5):483-5. PubMed ID: 12724740
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.